Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a challenging complication of many chemotherapeutic regimens. It is conventionally managed with antidepressants, antiepileptics, and adjuvants [1]. Neuromodulation, such as dorsal root ganglion (DRG) stimulation, is emerging as a potential treatment for refractory cases. First-line chemotherapy for multiple myeloma includes multiple CIPN-associated agents; however, the utility of DRG stimulation has not yet been described in this setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
